Stockhub

Tyra Biosciences, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 September 2022

  • curprev 00:5400:54, 27 September 2022‎ 95.149.241.133 talk‎ 838 bytes +838‎ Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/Tyra_Biosciences,_Inc.’